Health Care & Life Sciences » Biotechnology | Dyadic International Inc.

Dyadic International Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
17,134.70
12,523.40
315.70
592.90
758.40
1,295.50
Cost of Goods Sold (COGS) incl. D&A
9,113.00
8,186.90
124.00
516.20
680.20
1,027.30
Gross Income
8,021.80
4,336.50
191.70
76.70
78.20
268.20
SG&A Expense
7,548.60
9,390.60
2,506.00
4,794.70
7,233.40
7,839.80
EBIT
473.20
5,054.20
2,314.30
5,154.90
7,376.00
7,571.70
Unusual Expense
313.10
-
838.00
1,447.00
4,358.20
-
Non Operating Income/Expense
83.30
127.40
-
148.30
249.10
20.80
Interest Expense
686.00
683.20
-
-
-
-
Pretax Income
428.10
5,980.10
1,465.10
3,370.70
2,202.50
6,697.90
Income Tax
-
-
-
238.10
66.70
1,006.20
Consolidated Net Income
428.10
5,980.10
1,465.10
3,608.70
2,135.80
5,691.80
Net Income
428.10
5,980.10
1,465.10
3,608.70
2,135.80
5,691.80
Net Income After Extraordinaries
428.10
5,980.10
68,717.50
3,608.70
2,135.80
5,691.80
Net Income Available to Common
428.10
5,980.10
5,158.30
3,608.70
2,135.80
5,691.80
EPS (Basic)
0.01
0.18
1.91
0.10
0.07
0.21
Basic Shares Outstanding
32,797.30
34,073.50
34,367.70
36,538.40
28,918.00
27,673.30
EPS (Diluted)
0.01
0.18
1.91
0.10
0.07
0.21
Diluted Shares Outstanding
32,797.30
34,073.50
34,367.70
36,538.40
28,918.00
27,673.30
EBITDA
726.70
4,783.00
2,314.30
5,154.90
7,376.00
7,571.70
Other Operating Expense
-
-
-
436.90
220.70
-
Non-Operating Interest Income
14.60
28.10
11.20
485.50
566.10
894.50

About Dyadic International

View Profile
Address
140 Intracoastal Pointe Drive
Jupiter Florida 33477
United States
Employees -
Website http://www.dyadic.com
Updated 07/08/2019
Dyadic International, Inc. operates as a biotechnology company. It uses its patented and proprietary technologies for the discovery, development, manufacture, and sale of enzymes and other proteins for the bioenergy, biochemical, biopharmaceutical, and industrial enzyme industries. The company was founded by Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.